• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Virol . Intranasal nanoparticle vaccination elicits a persistent, polyfunctional CD4 T cell response in the murine lung specific for a highly con

tetano

Editor, Senior Moderator
J Virol


. 2021 Jun 2;JVI0084121.
doi: 10.1128/JVI.00841-21. Online ahead of print.
Intranasal nanoparticle vaccination elicits a persistent, polyfunctional CD4 T cell response in the murine lung specific for a highly conserved influenza antigen that are sufficient to mediate protection from influenza virus challenge


Sean A Nelson[SUP] 1 [/SUP], Thamotharampillai Dileepan[SUP] 2 [/SUP], Amy Rasley[SUP] 3 [/SUP], Marc K Jenkins[SUP] 2 [/SUP], Nicholas O Fischer[SUP] 3 [/SUP], Andrea J Sant[SUP] 1 [/SUP]



Affiliations

Abstract

Lung-localized CD4 T cells play a critical role in the control of influenza virus infection and can provide broadly protective immunity. However, current influenza vaccination strategies primarily target influenza hemagglutinin (HA) and are administered peripherally to induce neutralizing antibodies. We have used an intranasal vaccination strategy targeting the highly conserved influenza nucleoprotein (NP) to elicit broadly protective lung localized CD4 T cell responses. The vaccine platform consists of a self-assembling nanolipoprotein particle (NLP) linked to NP with an adjuvant. We have evaluated the functionality, in vivo localization and persistence of T cells elicited. Our study revealed that intranasal vaccination elicits a polyfunctional subset of lung-localized CD4 T cells that persist long term. A subset of these lung CD4 T cells localize to the airway, where they can act as early responders following encounter with cognate antigen. Polyfunctional CD4 cells isolated from airway and lung tissue produce significantly more effector cytokines IFNγ and TNFα as well as cytotoxic functionality. When adoptively transferred to naïve recipients, CD4 T cells from NLP:NP immunized lung were sufficient to mediate 100% survival from lethal challenge with H1N1 influenza virus. Importance Exploiting new, more efficacious strategies to potentiate influenza-specific immune responses is important, particularly for at-risk populations. We have demonstrated the promise of direct intranasal protein vaccination to establish long-lived immunity in the lung with CD4 T cells that possess features and positioning in the lung that are associated with both immediate and long-term immunity, as well as demonstrating direct protective potential.
 
Back
Top Bottom